N/A N=80 Effects of Obesity Treatments on Food Preferences and Metabolism
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Energy Intake From Baseline — 500; 310; 482; 5 kcal
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=102 Metformin in Overweight Type 2 Diabetes Mellitus
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
N/A N=14 The Effect of Hypoxia on Type 2 Diabetes and Weight Loss
Type2 Diabetes
Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=88 Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60
N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Phase 4 N=70 Mechanisms Underlying Metabolic Syndrome in Obesity
Metabolic Syndrome · Insulin Resistance · Prediabetes
Primary: Change in Insulin Sensitivity Using FSIGT — 1.7; 2.4; 7.02 FSIGT units (x10^-4/min/uU/ml)
Phase 4 N=32 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Type 2 Diabetes · Hypertension
Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg
N/A N=35 Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery
Type 2 Diabetes Mellitus · Obesity
Primary: Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6% — 4; 4 Participants
N/A N=28 Dopamine and Insulin Resistance
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
N/A N=45 Obesity, Sleep Apnea, and Insulin Resistance
Insulin Sensitivity · Obstructive Sleep Apnea
Primary: Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo — 35.8; 34.4 AHI events/hour
Phase 2 N=120 A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
Diabetes Mellitus Type 2
Primary: Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 — 0.0005; 0.0029; 0.0007; 0.0004 Percent Change
N/A N=32 The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes
Type 1 Diabetes
Primary: Energy Expenditure — 1978.3; 1969.8; 2414.8; 1497.7 Kilocalories — p=0.24
N/A N=28 Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises
Diabetes Mellitus, Type 2
Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml
N/A N=1,915 Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
N/A N=60 Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes
Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830
Phase 2 N=23 Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
Type 2 Diabetes Mellitus · Obese · Overweight
Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05
N/A N=48 An Analysis of Lipid and Glucose Metabolism Following Bariatric Surgery
Morbid Obesity
Primary: Triglycerides Post-prandial — 95; 71; 134 mmol/L
N/A N=601 Genetic Testing for Type 2 Diabetes
Diabetes Mellitus
Primary: Weight — 103.8; 100.7 kg — p=0.44
N/A N=62 A Comparison Chocolate With and Without High Cocoa Solids in Patients With Type 2 Diabetes in a Randomised Clinical Trial
Diabetes Type 2
Primary: Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake — 2.82; 2.21; 2.75 HOMA index
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
N/A N=86 Behavioral Change Communication for Physical Activity Among Females With Type2 Diabetes Mellitus
Physical Inactivity · Type2 Diabetes Mellitus
Primary: Total Physical Activity Log Means and Geometric Means With Standard Deviation in Intervention and Control Groups After Intervention. — 216.07; 201.47 log calories/day…
N/A N=67 Fit and Trim for Diabetes Prevention
Pre-diabetes · Overweight · Obese
Primary: Count of Participants Who Completed the Study — 28; 33 Participants
Phase 3 N=604 BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
Obesity
Primary: Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52 — 37.5; 44.7; 16.1 percentage of participants…
Phase 3 N=66 Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
Diabetes Prevention in Women After GDM Who Are at High-risk
Primary: Change in Body Weight — -21.5; -12.5; -4.4 kilograms — p=<0.032
N/A N=56 The Autonomic Nervous System and the Metabolic Syndrome
Obesity
Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min
Phase 4 N=43 Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
Type 2 Diabetes · Healthy · Impaired Glucose Tolerance
Primary: Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight — 5.5; 2.4; 2.7 kg — p=<0.05
N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01